Cure8 research brief
Using TDM to optimize vedolizumab could improve outcomes but may raise treatment costs; patients and clinicians should know cost-effectiveness depends heavily on drug price and local healthcare thresholds.
Clinicians and pharmacists managing biologic therapy, patients on or considering vedolizumab, health system payers, and researchers studying TDM or biologic cost-effectiveness.
The published abstract reports that TDM-guided vedolizumab produced small health gains (about 0.16 QALYs) but higher costs over a 10-year Markov model, yielding an ICER above the stated willingness‑to‑pay threshold in Cyprus, so the authors concluded it was not cost‑effective at current drug prices.
The analysis found that lowering vedolizumab acquisition costs or using managed-entry agreements that tie price to real‑world outcomes could change the conclusion. The authors also report decision uncertainty and an Expected Value of Perfect Information analysis suggesting further evidence would be valuable for Cyprus.
This brief is based on the article abstract and model summary provided in the PubMed entry; Cure8 has not reviewed the full study report or underlying data.
This is an economic modelling study from the Cypriot payer perspective with a 10-year horizon and is abstract-level content; results depend on model assumptions, local prices, and the chosen willingness‑to‑pay threshold. The PubMed entry provides an abstract summary, not full methods or patient-level results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If validated in clinical studies, extending the interval between subcutaneous vedolizumab doses could reduce injection frequency, costs, and treatment burden for some patients on maintenance therapy.
The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative...
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
